The topical use of timolol maleate might have also contributed to the development of hyperkalaemia by suppressing renin (and aldosterone) secretion.6 But hyperkalaemia was considered to be induced chiefly by the CAI, since timolol maleate was given throughout the entire clinical course and hyperkalaemia was not observed unless the CAI was given (Fig 1) . This is apparently the first report of hyperkalaemic metabolic acidosis induced by a CAI. CAIs could cause hyperkalaemia when given to patients who have a limited capacity for secreting potassium in the renal tubules, as seen in patients with renal dysfunction of tubular origin or to whom a ,3 adrenergic antagonist is given concomitantly.
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